Very Important Pool (VIP) genes--an application for microarray-based molecular signatures.
BACKGROUND
Advances in DNA microarray technology portend that molecular signatures from which microarray will eventually be used in clinical environments and personalized medicine. Derivation of biomarkers is a large step beyond hypothesis generation and imposes considerably more stringency for accuracy in identifying informative gene subsets to differentiate phenotypes. The inherent nature of microarray data, with fewer samples and replicates compared to the large number of genes, requires identifying informative genes prior to classifier construction. However, improving the ability to identify differentiating genes remains a challenge in bioinformatics.


RESULTS
A new hybrid gene selection approach was investigated and tested with nine publicly available microarray datasets. The new method identifies a Very Important Pool (VIP) of genes from the broad patterns of gene expression data. The method uses a bagging sampling principle, where the re-sampled arrays are used to identify the most informative genes. Frequency of selection is used in a repetitive process to identify the VIP genes. The putative informative genes are selected using two methods, t-statistic and discriminatory analysis. In the t-statistic, the informative genes are identified based on p-values. In the discriminatory analysis, disjoint Principal Component Analyses (PCAs) are conducted for each class of samples, and genes with high discrimination power (DP) are identified. The VIP gene selection approach was compared with the p-value ranking approach. The genes identified by the VIP method but not by the p-value ranking approach are also related to the disease investigated. More importantly, these genes are part of the pathways derived from the common genes shared by both the VIP and p-ranking methods. Moreover, the binary classifiers built from these genes are statistically equivalent to those built from the top 50 p-value ranked genes in distinguishing different types of samples.


CONCLUSIONS
The VIP gene selection approach could identify additional subsets of informative genes that would not always be selected by the p-value ranking method. These genes are likely to be additional true positives since they are a part of pathways identified by the p-value ranking method and expected to be related to the relevant biology. Therefore, these additional genes derived from the VIP method potentially provide valuable biological insights.
Su
Zhenqiang
Z
Center for Toxicoinformatics, National Center for Toxicological Research (NCTR), U,S, Food and Drug Administration (FDA), 3900 NCTR Road, Jefferson, AR 72079, USA. zhenqiang.su@fda.hhs.gov
Hong
Huixiao
H
Fang
Hong
H
Shi
Leming
L
Perkins
Roger
R
Tong
Weida
W
D000465:Algorithms; D020869:Gene Expression Profiling / Q000379:methods*; D005788:Gene Pool; D005796:Genes / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D020543:Proteome / Q000235:genetics*
D005819:Genetic Markers; D020543:Proteome
J Biol Chem. 2002 Nov 15;277(46):44399-407
12221094
BMC Bioinformatics. 2006 Feb 27;7:95
16504159
Cancer Cell. 2002 Mar;1(2):133-43
12086872
Comput Biol Chem. 2007 Feb;31(1):48-56
17303535
Comput Biol Chem. 2005 Feb;29(1):37-46
15680584
BMC Bioinformatics. 2007 Oct 03;8(1):370
17915022
J Immunol Methods. 2001 Apr;250(1-2):93-112
11251224
Bioinformatics. 2005 May 1;21(9):1979-86
15691862
Stat Med. 2007 Dec 20;26(29):5320-34
17624926
BMC Bioinformatics. 2006 May 02;7:235
16670007
Anal Chem. 2006 Jul 1;78(13):4564-71
16808466
J Natl Cancer Inst. 2003 Jan 1;95(1):14-8
12509396
Nat Rev Drug Discov. 2002 Dec;1(12):951-60
12461517
BMC Bioinformatics. 2008 Jan 24;9:42
18218074
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
11707567
Bioinformatics. 2003 Jun 12;19(9):1090-9
12801869
N Engl J Med. 2002 Jun 20;346(25):1937-47
12075054
Cancer Cell. 2002 Mar;1(2):203-9
12086878
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6562-6
11983868
Nat Rev Genet. 2001 Jun;2(6):418-27
11389458
BMC Bioinformatics. 2007 Mar 05;8:74
17338815
Nature. 2002 Jan 31;415(6871):530-6
11823860
Bioinformatics. 2005 Oct 1;21(19):3755-62
15817694
Bioinformatics. 2005 Jan 15;21(2):171-8
15308542
Bioinformatics. 2003 Jan;19(1):90-7
12499298
Bioinformatics. 2008 Feb 1;24(3):412-9
18175770
Curr Top Med Chem. 2004;4(13):1357-70
15379650
Mol Biol Cell. 2002 Jun;13(6):1929-39
12058060
Nature. 2002 Jan 24;415(6870):436-42
11807556
Lancet. 2005 Feb 5-11;365(9458):488-92
15705458
Science. 1995 Oct 20;270(5235):467-70
7569999
Bioinformatics. 2008 Mar 1;24(5):682-8
18204054
Nat Med. 2002 Aug;8(8):816-24
12118244
J Bioinform Comput Biol. 2005 Jun;3(3):627-43
16108087
Nat Med. 2002 Jan;8(1):68-74
11786909
BMC Bioinformatics. 2006 Jan 06;7:3
16398926
Bioinformatics. 2001 Dec;17(12):1131-42
11751221
J Comput Biol. 2000;7(3-4):559-83
11108479
Curr Opin Biotechnol. 2008 Feb;19(1):10-8
18155896
J Bioinform Comput Biol. 2005 Apr;3(2):185-205
15852500
Bioinformatics. 2006 Jan 1;22(1):88-95
16249260
Comput Biol Med. 2006 Jun;36(6):553-73
15978569
Nat Biotechnol. 1996 Dec;14(13):1675-80
9634850
Yearb Med Inform. 2006;:91-103
17051302
BMC Bioinformatics. 2004 Sep 27;5:136
15450124
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6745-50
10359783
Bioinformatics. 2006 Aug 1;22(15):1924-5
16709585
Bioinformatics. 2004 Dec 12;20(18):3583-93
15466910
Nat Biotechnol. 2006 Sep;24(9):1151-61
16964229
BMC Bioinformatics. 2005 Jul 15;6 Suppl 2:S12
16026597
Cancer Res. 2002 Sep 1;62(17):4963-7
12208747